Summary
PBMs will favor drugs that increase adherence to treatment in an effort to reduce pharmacy-related waste.
Amgen's Neulasta Delivery Kit will make treatment more efficient and will protect sales of the drug from biosimilar competition.
Amgen's Evolocumab will win favor with PBMs over competing PCSK9 inhibitors due to convenient administration with the Automated Mini-Doser and once per month dosing.
The stock price does not currently reflect these advantages.
http://ift.tt/1CbCJw6
PBMs will favor drugs that increase adherence to treatment in an effort to reduce pharmacy-related waste.
Amgen's Neulasta Delivery Kit will make treatment more efficient and will protect sales of the drug from biosimilar competition.
Amgen's Evolocumab will win favor with PBMs over competing PCSK9 inhibitors due to convenient administration with the Automated Mini-Doser and once per month dosing.
The stock price does not currently reflect these advantages.
http://ift.tt/1CbCJw6
Amgen Will Deliver in 2015
Aucun commentaire:
Enregistrer un commentaire